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Abstract
Background: Human encephalitis can originate from a variety of different aetiologies, of which infection is the
most common one. The diagnostic work-up is specifically challenging in patients with travel history since a broader
spectrum of unfamiliar additional infectious agents, e. g. tropical disease pathogens, needs to be considered. Here
we present a case of encephalitis of unclear aetiology in a female traveller returning from Africa, who in addition
developed an atypical herpes simplex virus (HSV) encephalitis in close temporal relation with high-dose steroid
treatment.
Case presentation: A previously healthy 48-year-old female presented with confusion syndrome and impaired
vigilance which had developed during a six-day trip to The Gambia. The condition rapidly worsened to a comatose
state. Extensive search for infectious agents including a variety of tropical disease pathogens was unsuccessful. As
encephalitic signs persisted despite of calculated antimicrobial and antiviral therapy, high-dose corticosteroids were
applied intravenously based on the working diagnosis of an autoimmune encephalitis. The treatment did, however,
not improve the patient’s condition. Four days later, bihemispheric signal amplification in the insular and
frontobasal cortex was observed on magnetic resonance imaging (MRI). The intracranial pressure rapidly increased
and could not be controlled by conservative treatment. The patient died due to tonsillar herniation 21 days after
onset of symptoms. Histological examination of postmortem brain tissue demonstrated a generalized lymphocytic
meningoencephalitis. Immunohistochemical reactions against HSV-1/2 indicated an atypical manifestation of
herpesviral encephalitis in brain tissue. Moreover, HSV-1 DNA was detected by a next-generation sequencing (NGS)
metagenomics approach. Retrospective analysis of cerebrospinal fluid (CSF) and serum samples revealed HSV-1 DNA
only in specimens one day ante mortem.
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Conclusions: This case shows that standard high-dose steroid therapy can contribute to or possibly even trigger
fulminant cerebral HSV reactivation in a critically ill patient. Thus, even if extensive laboratory diagnostics including
wide-ranging search for infectious pathogens has been performed before and remained without results, continuous
re-evaluation of potential differential diagnoses especially regarding opportunistic infections or reactivation of latent
infections is of utmost importance, particularly if new symptoms occur.
Keywords: Herpes simplex virus, Next generation sequencing, Encephalitis, Steroid, The Gambia, Travel associated,
Yellow fever vaccine associated neurological disease
Background
Clarification of the aetiology in a timely manner is
crucial regarding therapy and outcome of patients
presenting with symptoms of encephalitis [1], but also
in terms of hygiene measures, post exposure prophy-
laxis of contact persons, as well as epidemiological
(outbreak) control measures. The most common
causes of encephalitis are infections, in which viral in-
fections, especially herpes simplex virus type 1 (HSV-
1), account for the majority of cases [2]. However, de-
pending on the geographical region, a different
spectrum of pathogens needs to be considered. The
standard diagnostic procedures for patients with en-
cephalitis include magnetic resonance imaging (MRI)
or computed tomography (CT), analysis of CSF sam-
ples as well as electroencephalography (EEG). More-
over, brain biopsy may be sought to confirm an
inflammatory process. NGS (next-generation sequen-
cing) techniques are increasingly applied in diagnos-
tics, particularly in complex and unclear cases to
identify potential pathogens through metagenomic
analyses. These metagenomic analyses detect any frag-
ment of nucleic acid present in a specimen. Bioinfor-
matic downstream analyses can then align these
fragments into larger genomes and differentiate them
according to human, bacterial or viral origin, for ex-
ample. Apart from infections, autoantibodies in the
context of autoimmune diseases or paraneoplastic
syndromes have been increasingly recognized to be
associated with encephalitis and have to be included
into the differential diagnoses [3]. However, differenti-
ation between infectious and autoimmune encephalitis
can be challenging as there may be substantial over-
lap in their clinical presentation [4]. Here, we report
the case of a female traveller with encephalitis of un-
known aetiology after a trip to Africa who developed
atypical HSV-1 encephalitis in close temporal relation
with high-dose steroid therapy.
Case presentation
A 48-year-old Caucasian previously healthy female with-
out a history of recreational drug use developed confu-
sion syndrome and haemorrhagic cystitis during a travel
to The Gambia (Fig. 1). There she presented to a local
hospital, where trichomoniasis was diagnosed and
treated with antiparasitic chemotherapy. She decided to
interrupt the trip and returned to Munich, Germany
after only 6 days of travel (corresponds to “day one after
onset of symptoms” (DOS 1)). Upon return, the patient
was directly referred to a community hospital with
dizziness, blurred vision, confusion syndrome, and upper
arm pain. In the emergency department, she acutely
developed a delirious state with fluctuating vigilance and
had to be intubated. Laboratory testing revealed hypona-
tremia which was carefully corrected. While IL6 was
already slightly elevated (17.7 pg/μl [< 5.9 pg/ml]), CRP
(0.5 mg/dl [< 0.5 mg/dl]) and body temperature were
normal, no rash or neck stiffness were observed (Fig. 2).
Based on CSF pleocytosis (CSF cell count 33 cells/μl [< 5
cells/μl], CSF protein 30mg/dl [15–45 mg/dl], CSF lac-
tate 2.47 mmol/l [1.1–2.4 mmol/l], CSF glucose 78mg/dl
[50–90mg/dl], intact blood-CSF barrier), empiric anti-
biotic and antiviral treatment with ampicillin (12 g/d i.v.
for 11 days), ceftriaxone (4 g/d i.v. for 16 days) and
acyclovir (750 mg i.v. tid for 3 days) was started immedi-
ately upon admission to the emergency room, however,
as HSV-PCR was negative and imaging of the head and
brain (CT and MRI including angiography) was unsuspi-
cious, acyclovir treatment was ceased after 3 days.
Comprehensive microbiological testing for numerous in-
fectious pathogens including tropical and sexually trans-
missible pathogens, as well as search for autoantibodies
were unsuccessful (see Table 1). The results of testing
for yellow fever virus were compatible with a previous
vaccination which had been administered 10 days before
the travel to Africa. The EEG showed patterns of severe
diffuse encephalopathy. Since pulmonary gas exchange
and protective reflexes were adequate, the patient could
be extubated and was respiratory and hemodynamically
stable, though still unresponsive and alternating agitated
or somnolent. Ten days after the onset of symptoms, the
patient was transferred to a university hospital, where
microbiological and laboratory testing were intensified.
As the aetiology of the encephalitic syndrome was still
unclear, steroid pulse therapy was initiated under the ra-
tionale of suspected limbic encephalitis 12 days after
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symptom onset and continued for 5 days, but no clinical
improvement could be achieved. However, as on MRI
new bihemispheric insular and frontobasal signal en-
hancement appeared (Fig. 3) and since in parallel inflam-
matory markers started increasing, empiric antibiotic
therapy was again applied (meropenem 2 g i.v. tid from
DOS 16 on, vancomycin i.v. [trough level 10–15 μg/dl]
from DOS 18 on). Since the state of vigilance was still
unchanged and protective reflexes were absent, the
patient was re-intubated. Moreover, facial myoclonus
emerged, which was treated with levetiracetam and
phenytoin. As the anticonvulsive therapy was insufficient
to control the myoclonus, therapeutic sedation was initi-
ated, under which no spikes were detectable any more
on EEG. Two days later, anisocoria (r > l) was noticed
and conservative treatment of the underlying increased
intracranial pressure (ICP) was started with osmothera-
peutics, deep anaesthesia (including barbiturate), and
hyperventilation. Neurosurgical therapy options were
discussed, however, not feasible because of progressive
and generalized oedematous brain swelling with trans-
tentorial and foraminal herniation. The patient showed
fixed dilated pupils and died 1 day later, 21 days after
first symptom onset. As the cause of the disease was
completely unclear, autoptic examination was sought
which could help to explain at least the final course of
the disease. Below, the most important results of the
diagnostic investigations are presented and discussed in
detail.
Diagnostic focus and assessment
Pathogen diagnostics
During the course of the disease, numerous laboratory
examinations were performed in an attempt to identify
infectious pathogens potentially responsible for the
patient’s encephalitis (see Table 1). For this reason,
blood, CSF, urine, stool, and respiratory samples were
also repeatedly applied to microbiological cultures which
did not detect any relevant pathogens. For differential
diagnosis, methods were selected according to different
criteria: (I) The most common pathogens were analysed
by multiplex PCR from CSF (cytomegalovirus (CMV),
enterovirus, herpes simplex virus-1/2 (HSV-1/2), human
herpes virus 6 (HHV6), human parechovirus, varicella
zoster virus (VZV), Escherichia coli K1, Haemophilus
influenzae, Listeria monocytogenes, Neisseria meningiti-
dis, Streptococcus agalactiae, Streptococcus pneumoniae,
Cryptococcus neoformans/gattii). (II) A group of
pathogens was investigated because of the travel history
(chikungunya virus, dengue virus, Mycobacterium
tuberculosis, Plasmodium sp., rabies virus, Rift Valley
virus, sandfly fever virus, Trypanosoma sp., West Nile
virus, yellow fever virus, Zika virus) or (III) because of a
potential risk profile that could not be specifically asked
Fig. 1 Timeline
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(HIV, hepatitis viruses, Treponema pallidum). (IV)
Moreover, (zoonotic) pathogens which may have been
acquired before the journey (Borna disease virus 1
(BoDV-1), Borrelia burgdorferi, Japanese encephalitis
virus, Leptospira sp., tick-borne encephalitis virus) or (V)
which are rare or very rare pathogens of encephalitis
(Ebstein Barr virus, lymphocytic choriomeningitis virus,
measels virus, rubella virus) were examined.
Yellow fever vaccine-associated neurological disease (YEL-
AND) and autoimmune encephalitis
Since the patient had received yellow fever vaccination
in preparation for her travel, the presence of a yellow
fever vaccine associated neurotropic syndrome was
considered. Anti-yellow fever antibodies in the patient’s
serum were within the range of a normal post-
vaccination immune response and were not detected in
the cerebrospinal fluid. No yellow fever vaccine virus
RNA could be amplified from any sample (brain biop-
sies, cerebrospinal fluid, serum, urine). Therefore, YEL-
AND could not be confirmed.
The investigation of a broad spectrum of neuronal auto-
antibodies (against AMPAR1/2, amphiphysin, aquaporin
4, Ca-channel, CASPR2, CV2 (CRMP5), GABARB1/2,
GAD, Hu, LGI-1, Ma1/2, NMDAR, Purkinje cells, Ri, Yo)
remained without pathological findings and thus, no evi-
dence for an autoimmune-mediated encephalitis existed.
Autopsy
On autopsy, neuropathological examination of the brain
demonstrated macroscopically oedematous swelling and
signs of increased intracranial pressure with sulcal ef-
facement, uncus herniation, and discretely prominent
cerebellar tonsils (Fig. 4a). Temporally accentuated
haemorrhagic necrosis, which is typically observed in
classical cases of herpesviral encephalitis, were not seen
(Fig. 4b). Histological examination revealed lymphocytic
meningoencephalitis with plenty of perivascular and
intraparenchymal T-lymphocytes (Fig. 4c and d). The
diagnosis of herpesviral encephalitis was made based on
the immunohistochemical detection of numerous in-
fected neurons that stained positive for HSV-1 (Fig. 4e).
NGS analysis
NGS analysis was performed with DNA and RNA iso-
lated from native autopsy tissue of the frontal lobe and
cerebellum together with preserved serum from DOS 21.
The number of reads that could be assigned to viral
specimens was highest in material from the frontal lobe
(Table 2). The majority of those reads belonged to the
human alpha-herpesvirus type 1 (HSV-1) (Fig. 5).
After HSV DNA and antigen were detected in autopsy
specimens of the brain by NGS analysis and immunohis-
tochemical detection, respectively, retrospective conven-
tional single PCR analyses from archived CSF, serum
and tissue were performed to confirm these results (see
below and Table 3).
Discussion and conclusions
Patients with encephalitis need to be diagnosed and ap-
propriately treated in a timely manner. Viral infections
account for the majority of cases (42%) followed by
Fig. 2 Laboratory results. Chronological visualization of relevant values from cerebrospinal fluid (cell count [< 5 cells/μl] and protein concentration
[15–45mg/dl]), serum (C-reactive protein (CRP) [< 0.5 mg/dl] and interleukin 6 (IL6) [< 5.9 pg/ml]) and white blood cell (WBC) count [40–104 G/dl]
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autoimmune-mediated encephalitis (21%), while about
40% of the patients remain without a final diagnosis [2].
In our case, the clinical suspicion of encephalitis
quickly emerged and was supported by results of lumbar
puncture and EEG. In the initial phase of the disease,
diagnostic imaging (CT and MRI) could not reveal a
morphological correlate with these findings and the pa-
tient’s symptoms. However, a vascular or malignant
cause of the disease could be excluded in this way. HSV
encephalitis is the most common sporadic form of en-
cephalitis in Western Europe. There is an international
consensus to carry out a rapid diagnosis using PCR from
the CSF and to administer a empiric therapy with
acyclovir. Such measures reduce the lethality of HSV en-
cephalitis from about 70 to 30% [5].
Empiric antibiotic and antiviral treatment was immedi-
ately started upon admission to hospital according to the
current guidelines of the German Society for Neurology
[6, 7], so that there was no delay in therapy initiation.
Although HSV-PCR from CSF in the early phase of HSV
encephalitis does not reach a sensitivity of 100% [8],
acyclovir therapy was terminated after 3 days. This dis-
continuation of the empirical acyclovir therapy was justi-
fied by the lack of strong clinical suspicion of a very rare
‘PCR negative’ HSV encephalitis: Repeated cranial im-
aging (CT and MRI) without abnormal findings and the
first clinical improvement allowing an extubation after 6
days were the evidence for this therapeutic decision.
After transfer to the university hospital, a second HSV-
PCR from CSF performed on day 10 – after an acyclovir
break of several days – was also negative and underlined
that HSV was extremely unlikely to be the causative
pathogen of the patient’s encephalopathy presented at
this time. Moreover, a repeatedly normal serum CSF
antibody specificity index for HSV throughout the dis-
ease duration (21 days) showed that HSV encephalitis di-
agnosed post mortem must indeed have developed
towards the end of the clinical course (Table 3).
A travel-associated infectious disease was considered
an important differential diagnosis from the very first
moment due to the presented neurological symptoms
associated with a journey abroad [9]. All relevant patho-
gens were examined after an evaluation of the potential
exposure risk [10]. However, in this context, it must also
be discussed, whether the very short duration of the stay
abroad equals an appropriately long incubation period
for an acute infection. Therefore, emerging viruses that
may have been acquired before the journey, such as zoo-
notic Borna viruses (BoDV-1 and VSBV-1), were also
taken into account.
In addition to the targeted search for pathogens, the
‘extended’ microbiological diagnosis in such a travel-
related case must include vaccines applied in a close
temporal connection as well as medication already
Table 1 Infectious disease work-up
Pathogen DOS Method Specimen
Borna disease virus-1 21 PCR CSF
Borrelia burgdorferi 10 Ig, AI CSF, S
Chikungunya virus 10 Ig S
Cryptococcus neoformans/gatti 10 PCR CSF
Cytomegalovirus 2, 10 PCR, Ig, AI CSF, S
Dengue virus 10, 11 Ig S
Ebstein Barr virus 10 PCR, Ig, AI CSF, S
Enterovirus 10 PCR CSF
Escherichia coli K1 10 PCR CSF
Flaviviruses 21 PCR CSF
Haemophilus influenzae 10 PCR CSF
Hepatitis A virus 10 Ig S
Hepatitis B virus 10 Ig, Ag S
Hepatitis C virus 10 Ig S
Herpes simplex virus 1/2 2, 10 PCR, Ig, AI CSF, S
Human herpes virus 6 10 PCR S
Human immunodeficiency virus 10 Ig, Ag S
Japanese encephalitis virus 11 Ig S
Leptospira sp. 10 Ig S
Listeria monocytogenes 10 PCR CSF
Lymphocytic choriomeningitis
virus
10 Ig CSF, S
Measels virus 10 AI CSF, S
Mycobacterium tuberculosis 17 QFT B
Neisseria meningitidis 10 PCR CSF
Parechovirus 10 PCR CSF
Plasmodium sp. 19 RT, M S
Rabies virus 10 PCR CSF
Rift Valley virus 11 PCR, Ig S
Rubella virus 10 AI CSF, S
Sandfly fever virus 10 Ig S
Streptococcus agalactiae 10 PCR CSF
Streptococcus pneumonieae 10 PCR CSF
Tick-borne encephalitis virus 10, 11 Ig CSF, S
Treponema pallidum 2, 10 Ig S
Trypanosoma brucei gambiense/
rhodesiense
2 PCR, Ig S
Trypanosoma cruzi 2 Ig S
Varicella zoster virus 10 PCR, Ig, AI CSF, S
Variegated squirrel bornavirus-1 21 PCR CSF
West Nile virus 10, 11 Ig S
Yellow fever virus 2, 9, 11, 17, 21 PCR, Ig CSF, S, A
Zika virus 10 PCR, Ig S
Evaluated pathogens with negative findings
DOS Days after onset of symptoms, Ig Serology, AI pathogen specific
CSF/serum antibody index, S Serum, Ag Antigen-Test, QFT Quantiferon
test, B Blood, RT Rapid test, M Microscopy, A autopsy tissue
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administered on site. A first important aspect of the pa-
tient’s travel-related vaccination record is the correctly
administered yellow fever vaccination 2 weeks before de-
parture. YEL-AND is a serious side effect after primary
vaccination [11]. The frequency is given as approx. 0.8/
100,000 doses. Typically, patients develop meningo-
encephalitis 14 (3–28) days after administration but
recover without sequelae. This infection of the CNS by
the vaccine virus itself can be detected by the detection
of yellow fever vaccine RNA or yellow fever virus-
specific antibodies in the cerebrospinal fluid [12]. Few
data suggest that yellow fever vaccination may trigger an
autoimmune response and cause symptoms such as
Guillain-Barré syndrome, multiple sclerosis or acute de-
myelinating encephalomyelitis (ADEM) [13]. However,
as described above, there was no evidence of YEL-AND
in our case.
Another important point of the travel history is that
haemorrhagic cystitis with proven Trichomonas infection
was already treated with antibiotics during the stay in
The Gambia. Even if the exact active substance was not
traceable, a therapy with metronidazole seems to be very
likely. Metronidazole-induced encephalopathies de-
scribed in the literature differ in their typical clinical
course from our case [14]. Nevertheless, we cannot
exclude such a possible or other (unknown) drug side
effect as the cause of the persistent impaired conscious-
ness in the retrospective assessment of the case.
We had expected that the NGS analysis from the brain
tissue samples would detect unanticipated or possibly
even novel pathogens, which was, however, not the case.
Nevertheless, reduced sensitivity remains a weakness of
this method. In our case study, for example, an HSV
load of 1000 Geq/ml detectable in serum by routine
Fig. 3 cMRI imaging. Cortical/subcortical oedema within insular and parietal lobe on coronal and axial T2w (a, b), coronal DWI with increased
signal on B1000 image (c) and decreased ADC (apparent diffusion coefficient) (d) within the encephalitic lesion
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PCR could not generate HSV reads in the NGS investi-
gation of the serum at the same point in time (compare
Tables 2 and 3). This may be relevant because it cannot
be excluded that the initial phase of the disease was
caused by an unknown pathogen other than HSV and
not by autoimmune disease. The viral load in brain tis-
sue may have fallen below the lower detection limit of
the NGS analysis over the course of the disease. Never-
theless, in our case we estimate the probability of not
being able to detect a previously unknown pathogen
after 21 days of illness in a brain biopsy via NGS as low.
Even today, it is estimated that approximately half of all
encephalitis cases remain without identification of a clear
cause [2, 15]. Despite advancing diagnostic options from
multiplex PCR systems to NGS technology, this gap in
clinical microbiology is not closed. Publications on NGS
metagenomic analyses in patients with encephalitis show
that known and common encephalitis pathogens but also
rare, unexpected, or even novel organisms can be detected
in patient samples [16–18].
The HSV-reactivation presented as an atypical mani-
festation of HSV-1 encephalitis without the temporally
and frontally accentuated haemorrhagic necroses which
are typically observed on imaging and autopsy. Such
atypical manifestations of HSV-1 encephalitis can be ob-
served in immunosuppressed or critically ill patients
[19–21] and impede making the correct diagnosis.
Histological examination demonstrated pronounced
lymphocytic meningoencephalitis with immunohisto-
chemical detection of HSV-1 antigens. Due to the exten-
sive destruction of the brain tissue, any signs, allowing
conclusions towards the aetiology of the initial disease
could not be assessed.
In animal models, the hypothesis that naturally occur-
ring stressful situations in the host lead to reactivation
of latent herpes viruses due to increased endogenous
corticosteroid release was supported early on [22]. The
effects of corticosteroids on the gene expression of the
cell and latent virus, which occur a few hours after injec-
tion, can lead to an altered balance between herpes virus
and neuron and can lead to the death of the neuron by
Fig. 4 Neuropathological autopsy findings. Oedematous swelling with sulcal effacement and signs of transtentorial and tonsillar herniation (a).
Symmetrical, though remarkably compressed ventricular system reflecting the increased intracranial pressure (b). Histological examination showed
lymphocytic meningoencephalitis with marked perivascular and intraparenchymal lymphocyte infiltration (c). The infiltrates are primarily
composed of CD3-positive T-lymphocytes (d). Numerous infected neurons demonstrated by HSV-1 immunohistochemistry (e). Magnification (c)-
(e): 20x; Scale bar: 50 μm
Table 2 Results of NGS analysis
Material RNA/DNA [ng/μl] Reads total Reads HSV-1
Frontal lobe RNA 0.47 4,252,804 4188 (0.10%)
Frontal lobe DNA 1.5 2,186,683 490 (0.02%)
Cerebellum RNA 0.39 4,983,018 0
Serum (DOS 21) RNA 0.42 2,523,808 0
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switching the virus into a lytic replication cycle, even
with a single dose of dexamethasone.
Although it is well known that steroid therapy can
cause HSV reactivation in neurons in animal models,
only few cases have been reported in the literature
in which HSV reactivation and encephalitis coincided
with steroid therapy in humans [23]. Of note, most
of the described treatment regimens consisted of a
combination with other stress-inducing or immuno-
suppressive therapies such as irradiation or chemo-
therapy [24, 25]. Therefore, HSV reactivation and
atypical herpesviral encephalitis should be considered
as relevant differential diagnosis in iatrogenically
immunosuppressed patients in general and especially
after high-dose steroid therapy. Moreover, a recent
study suggests that atypical presentations of HSV
encephalitis might be more frequent than expected
so far [26].
In summary, our case represents the reactivation of
HSV-1 infection, likely triggered by steroid therapy in
the context of a pre-existing severe encephalitis of
unknown cause. In order to not overlook newly oc-
curred and potentially treatable entities, continuous
re-evaluation of potential differential diagnoses, espe-
cially regarding opportunistic infections or reactiva-
tion of latent infections, is of utmost importance.
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